Metformin effectively treats Tsc1 deletion-caused kidney pathology by upregulating AMPK phosphorylation
- Yili Fang,
- Fang Li,
- Chenyang Qi,
- Xing Mao,
- Feng Wang,
- Zhonghua Zhao
- Fudan University,
- Shanghai Jiao Tong University,
- ,
- Augusta University
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Tuberous sclerosis complex (TSC) is characterized by hamartomatous lesions in multiple organs, with most patients developing polycystic kidney disease and leading to a decline of renal function. TSC is caused by loss-of-function mutations in either Tsc1 or Tsc2 gene, but currently, there is no effective treatment for aberrant kidney growth in TSC patients. By generating a renal proximal tubule-specific Tsc1 gene-knockout (Tsc1<sup>ptKO</sup>) mouse model, we observed that Tsc1<sup>ptKO</sup> mice developed aberrantly enlarged kidneys primarily due to hypertrophy and proliferation of proximal tubule cells, along with some cystogenesis, interstitial inflammation, and fibrosis. Mechanistic studies revealed inhibition of AMP-activated protein kinase (AMPK) phosphorylation at Thr-172 and activation of Akt phosphorylation at Ser-473 and Thr-308. We therefore treated Tsc1<sup>ptKO</sup> mice with the AMPK activator, metformin, by daily intraperitoneal injection. Our results indicated that metformin increased the AMPK phosphorylation, but decreased the Akt phosphorylation. These signaling modulations resulted in inhibition of proliferation and induction of apoptosis in the renal proximal tubule cells of Tsc1<sup>ptKO</sup> mice. Importantly, metformin treatment effectively prevented aberrant kidney enlargement and cyst growth, inhibited inflammatory response, attenuated interstitial fibrosis, and protected renal function. The effects of metformin were further confirmed by in vitro experiments. In conclusion, this study indicates a potential therapeutic effect of metformin on Tsc1 deletion-induced kidney pathology, although currently metformin is primarily prescribed to treat patients with type 2 diabetes.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Article number
52Journal (Volume, Issue Number)
Cell Death Discovery (Volume 6, Issue 1)Publication milestones
- Published - 12/01/2020
Publication status
Published - 12/01/2020
Publication IDs
- Scopus: 85086471833
Publication metrics
Metrics
SciVal
FWCI
1.30
SciVal
Author count
9
SciVal
citations
4
SciVal
Paper percentile
88
Fractional count
1
Fractional count
0.11
Fractional count
8
Fractional count
0.89
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Captures
23
Citation count
18
Funding Details
This work was supported by grants from the Science and Technology Commission of Shanghai Municipality (No. 15140902900).
FunderFunding number
STCSM
15140902900
